389 related articles for article (PubMed ID: 19227609)
1. [Anti-VEGF therapy with bevacizumab in breast cancer].
Tóth J; Gonda A; Szántó J
Lege Artis Med; 2008 Oct; 18(10):669-73. PubMed ID: 19227609
[TBL] [Abstract][Full Text] [Related]
2. The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab.
Marty M; Pivot X
Eur J Cancer; 2008 May; 44(7):912-20. PubMed ID: 18396037
[TBL] [Abstract][Full Text] [Related]
3. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer.
de Gramont A; Van Cutsem E
Oncology; 2005; 69 Suppl 3():46-56. PubMed ID: 16301835
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab in the treatment of breast cancer.
Koutras AK; Fountzilas G; Makatsoris T; Peroukides S; Kalofonos HP
Cancer Treat Rev; 2010 Feb; 36(1):75-82. PubMed ID: 19932567
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
Shih T; Lindley C
Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
[TBL] [Abstract][Full Text] [Related]
6. Safety of bevacizumab in patients with metastatic breast cancer.
Hamilton EP; Blackwell KL
Oncology; 2011; 80(5-6):314-25. PubMed ID: 21778772
[TBL] [Abstract][Full Text] [Related]
7. The combination of VEGF inhibitors and anti-oestrogen therapies in breast cancer.
Banerjee S
Steroids; 2011 Jul; 76(8):807-11. PubMed ID: 21439993
[TBL] [Abstract][Full Text] [Related]
8. Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer.
Aita M; Fasola G; Defferrari C; Brianti A; Bello MG; Follador A; Sinaccio G; Pronzato P; Grossi F
Crit Rev Oncol Hematol; 2008 Dec; 68(3):183-96. PubMed ID: 18606548
[TBL] [Abstract][Full Text] [Related]
9. Evolution of bevacizumab-based therapy in the management of breast cancer.
Sachdev JC; Jahanzeb M
Clin Breast Cancer; 2008 Oct; 8(5):402-10. PubMed ID: 18952553
[TBL] [Abstract][Full Text] [Related]
10. Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer.
Sandler AB; Johnson DH; Herbst RS
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4258s-4262s. PubMed ID: 15217970
[TBL] [Abstract][Full Text] [Related]
11. The role of antiangiogenetic agents in the treatment of breast cancer.
Bareschino MA; Schettino C; Colantuoni G; Rossi E; Rossi A; Maione P; Ciardiello F; Gridelli C
Curr Med Chem; 2011; 18(33):5022-32. PubMed ID: 22050750
[TBL] [Abstract][Full Text] [Related]
12. VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy.
Burstein HJ; Chen YH; Parker LM; Savoie J; Younger J; Kuter I; Ryan PD; Garber JE; Chen H; Campos SM; Shulman LN; Harris LN; Gelman R; Winer EP
Clin Cancer Res; 2008 Dec; 14(23):7871-7. PubMed ID: 19047116
[TBL] [Abstract][Full Text] [Related]
13. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer.
Chase JL
Pharmacotherapy; 2008 Nov; 28(11 Pt 2):23S-30S. PubMed ID: 18980549
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab in the treatment of metastatic colorectal cancer.
Caprioni F; Fornarini G
Future Oncol; 2007 Apr; 3(2):141-8. PubMed ID: 17381413
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab in the treatment of metastatic breast cancer.
Traina TA
Oncology (Williston Park); 2009 Apr; 23(4):327-32. PubMed ID: 19476261
[TBL] [Abstract][Full Text] [Related]
16. Experience with bevacizumab in the management of epithelial ovarian cancer.
Burger RA
J Clin Oncol; 2007 Jul; 25(20):2902-8. PubMed ID: 17617521
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer.
Krämer I; Lipp HP
J Clin Pharm Ther; 2007 Feb; 32(1):1-14. PubMed ID: 17286784
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanced breast cancer.
Damasceno M
Curr Opin Oncol; 2011 Apr; 23 Suppl():S3-9. PubMed ID: 21490481
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab for advanced breast cancer.
Traina TA; Rugo HS; Dickler M
Hematol Oncol Clin North Am; 2007 Apr; 21(2):303-19. PubMed ID: 17512451
[TBL] [Abstract][Full Text] [Related]
20. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
Grothey A; Ellis LM
Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]